US drug manufacturers generally displayed strength as solid defensive picks for investors in uncertain times in the second quarter, delivering modest sales and earnings growth, with few exceptions, despite a wide array of macro-economic pressures and a strong US dollar that knocked growth from the top line.
Big pharmas tend to be resilient business operations in challenging macro climates and 2022 has delivered plenty of twists and...